Novavax
NVAX
$4.09
Share price
3.54%
Change (1 day)
-45.68%
Change (1 year)
Categories
P/S ratio for Novavax (NVAX)
P/S ratio as of April 2024 (TTM): 0.8249
According to Novavax's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.824932. At the end of 2023 the company had a P/S ratio of 0.8222.
P/S ratio history for Novavax from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 0.8222 | 31.11% |
| 2022 | 0.6271 | -93.35% |
| 2021 | 9.44 | -36.78% |
| 2020 | 14.9 | 116.33% |
| 2019 | 6.90 | -66.56% |
| 2018 | 20.6 | 38.17% |
| 2017 | 14.9 | -32.93% |
| 2016 | 22.3 | -64.37% |
| 2015 | 62.5 | 35.26% |
| 2014 | 46.2 | -9.57% |
| 2013 | 51.1 | 303.3% |
| 2012 | 12.7 | 28.42% |
| 2011 | 9.86 | -98.75% |
| 2010 | 787 | -4.14% |
| 2009 | 821 | 567.88% |
| 2008 | 123 | -22.27% |
| 2007 | 158 | 192.21% |
| 2006 | 54.1 | 89.67% |
| 2005 | 28.5 | 97.4% |
| 2004 | 14.4 | -18.25% |
| 2003 | 17.7 | 286.66% |
| 2002 | 4.57 | -66.51% |
| 2001 | 13.6 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 3.90 | 372.46% | 🇨🇭 Switzerland |
 Pfizer PFE | 2.46 | 197.93% | 🇺🇸 USA |
 AstraZeneca AZN | 5.09 | 516.71% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 2.22 | 169.42% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | 9.81 | 1,088.61% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 346 | 41,901.76% | 🇺🇸 USA |
 Agenus
AGEN | 1.59 | 92.33% | 🇺🇸 USA |
 NanoViricides NNVC | N/A | N/A | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | 2.59 | 214.06% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.0983 | -88.09% | 🇺🇸 USA |